Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models
Wang, Xiao-Xiao, et al. Frontiers in Medicine 10 (2023): 1172058.
Categories: Publications
Caloric Restriction Combined with Immobilization as Translational Model for Sarcopenia Expressing Key- Pathways of Human Pathology
de Jong, Jelle CBC, et al. Aging and Disease 14.3 (2023): 937.
Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study
Anstee, Quentin M., et al. Hepatology: 10-1097.
Second-Harmonic Generated Quantifiable Fibrosis Parameters Provide Signatures for Disease Progression and Regression in Nonalcoholic Fatty Liver Disease
Ng, Nicole, et al. Clinical Pathology 16 (2023): 2632010X231162317.
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
Sanyal, Arun J., et al. Nature Medicine 29.2 (2023): 392-400.
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis
Noureddin, Mazen, et al. Alimentary Pharmacology & Therapeutics 57.4 (2023): 409-417.
Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH
Naoumov, Nikolai V., et al. Journal of Hepatology 77.5 (2022): 1399-1409.
Developing a New qFIBS Model Assessing Histological Features in Pediatric Patients With Non-alcoholic Steatohepatitis
Liu, Feng, et al. Frontiers in Medicine 9 (2022): 925357.
Artificial Intelligence Improves Pathologist Agreement for Fibrosis Scores in Nonalcoholic Steatohepatitis Patients
Soon, Gwyneth ST, et al. Clinical Gastroenterology and Hepatology (2022).
Breakthroughs in therapies for NASH and remaining challenges
Ratziu, Vlad, et al. Journal of Hepatology 76.6 (2022): 1263-1278.